ACTIVE_NOT_RECRUITING

Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis

Conditions

Idiopathic Subglottic Stenosis IL-17a inhibition

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this phase 2 study is to examine if inhibiting IL-17A activation using the biologic drug Taltz, in idiopathic subglottic stenosis patients will decrease scar fibroblast proliferation therefore reducing or eliminating the need for invasive or repeat surgeries.

Official Title

Effects of IL-17A Inhibition on Idiopathic Subglottic Stenosis

Quick Facts

Study Start:2025-02-20

Study Completion:2026-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05309616

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * diagnosis of idiopathic subglottic stenosis	* History of active or latent tuberculosis infection * History of inflammatory bowel disease * Pregnancy or lactation * Known allergic reactions to study drug * Disease involving the vocal cords * Individuals who are taking drugs known to trigger angioedema, including use acquired angioedema from drugs such as ACE inhibitors (e.g. Lisinopril) and nonsteroidal anti-inflammatory drugs (NSAIDs) and individuals with a history of other forms of angioedema such as hereditary and Clesterase deficiency

Inclusion Criteria

Exclusion Criteria

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* diagnosis of idiopathic subglottic stenosis

* History of active or latent tuberculosis infection
* History of inflammatory bowel disease
* Pregnancy or lactation
* Known allergic reactions to study drug
* Disease involving the vocal cords
* Individuals who are taking drugs known to trigger angioedema, including use acquired angioedema from drugs such as ACE inhibitors (e.g. Lisinopril) and nonsteroidal anti-inflammatory drugs (NSAIDs) and individuals with a history of other forms of angioedema such as hereditary and Clesterase deficiency

Contacts and Locations

Principal Investigator

Nwanmegha Young, MD

PRINCIPAL_INVESTIGATOR

Yale University

Study Locations (Sites)

Yale New Haven Hospital

New Haven, Connecticut, 06520

United States

Collaborators and Investigators

Sponsor: Yale University

Nwanmegha Young, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-20

Study Completion Date2026-05

Study Record Updates

Study Start Date2025-02-20

Study Completion Date2026-05

Terms related to this study

Keywords Provided by Researchers

IL-17a inhibition

Additional Relevant MeSH Terms

Idiopathic Subglottic Stenosis